RBS Global Big Pharma ETN(DRGS)- NYSEARCA
DRGS is defunct since July 7, 2015. Lack of investor interest
  • Mar. 19, 2015, 11:45 AM
    • In a report published by EP Vantage (the editorial arm of market intelligence firm Evaluate), 2014 was the year of biotech. Highlights include:
    • $212B in M&A transactions, eclipsing 2009's $152B; 87 IPOs that raised $6.3B (almost double the floats done in 2013 and more than 2x money raised); $6.5B in venture funding (+33%).
    • FDA approved a record 50 new drugs.
    • So far in 2015, ~$3B has been raised through secondary offerings.
    • ETFs: IBB, BIB, IRY, BIS, IXJ, DRGS
    | Mar. 19, 2015, 11:45 AM | 7 Comments
  • Nov. 21, 2014, 11:46 AM
    • CB Pharma Acquisition Corp. (CNLMU) files for an IPO of 4M units priced at $10 per unit. Each unit consists of one share of common stock, one right to purchase 1/10 of a share of common stock on the consummation of an initial business combination and one warrant to purchase 1/2 of one share of common stock at a full-share price of $11.50.
    • The firm is a blank check company formed by Coronado Biosciences (CNDO +0.5%). It will seek business combinations via mergers, share exchanges, asset acquisitions, share purchases, recapitalizations or reorganizations.
    • It has 18 months from the consummation of this offering to complete its initial business combination (up to 21 months in certain circumstances) or it will liquidate the trust account, distribute the proceeds to shareholders and dissolve.
    • Per NASDAQ listing rules, the target business for the initial combination must have a fair market value equal to at least 80% of the value of the trust account.
    • ETFs: IBB, BIB, IRY, BIS, IXJ, DRGS (NYSEARCA:IPO)
    | Nov. 21, 2014, 11:46 AM
  • Jul. 7, 2014, 1:32 PM
    • Bloomberg reports that privately-held Omega Pharma N.V. is exploring a sale of the company for as much as $4B. The Belgian firm was taken private ~three years ago by the founder.
    • ETFs: IBB, BIB, IRY, IXJ, BIS, EWK, DRGS
    | Jul. 7, 2014, 1:32 PM
  • Apr. 22, 2014, 12:14 PM
    | Apr. 22, 2014, 12:14 PM
  • Dec. 14, 2011, 7:50 AM
    Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity.
    | Dec. 14, 2011, 7:50 AM
DRGS Description
The RBS Global Big Pharma ETNs are designed for investors who seek exposure to the NYSE Arca Equal Weighted Pharmaceutical Total Return Index (the “Index”). The Index is designed to track the performance of the equity securities of a cross section of companies involved in various phases of development, production and marketing of pharmaceuticals, with the component securities represented in approximately equal dollar amounts. The Index is rebalanced quarterly at the close of trading on the third Friday of March, June, September and December.
See more details on sponsor's website
Sector: Healthcare
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub